24 February 2026 - 25 February 2026
08018 Barcelona, Spain
Avenida Diagonal 201
Novotel Barcelona City
European Drug Safety & AI 2026
What to expect
AI is already used in pharmacovigilance, but discussions often remain surface-level. As validated tools emerge, the focus shifts from if to how – gaining competitive advantage, ensuring transparency, and extracting value from new technologies. Regulators like EMA and FDA offer guidance, yet challenges persist around validating learning systems, justifying AI-driven signals, and shaping regulations.
AI is also changing PV roles, requiring new skills and workforce retraining. Ethical concerns like bias and underrepresentation must be addressed. We invite you to explore these critical issues at the European Drug Safety & AI 2026.
Conference format
Our 2-day conference is tailored to support you in addressing key challenges at the intersection of pharmacovigilance and AI—whether it’s optimizing signal detection with limited resources, integrating AI into case processing, or ensuring compliance while adopting advanced automation in safety systems.
In addition to our trusted formats – Keynotes, Case Studies, and Panel Discussions – we are introducing new interactive sessions to deepen learning and real-world application:
Key Takeaways
Contact Us
Jan Cizek | Attending
Producer
Lubos Kusy | Attending and Sponsoring
Business Development Manager